Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 4, 2014, Pages 493-502

  Knöbl, Paul ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ADAMTS13; platelets; thrombotic microangiopathy; thrombotic thrombocytopenic purpura; von Willebrand factor

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APTAMER; ARC 15105; BENDAMUSTINE; CAPLACIZUMAB; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EGAPTIVON PEGOL; HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRASUGREL; RECOMBINANT PROTEIN; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; RITUXIMAB; THROMBOCYTE CONCENTRATE; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; ARC15105; COMPLEMENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NANOBODY;

ADULT; ADULT DISEASE; ANEMIA; ARTICLE; BLINDNESS; CLINICAL FEATURE; CONTINUOUS INFUSION; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HEADACHE; HUMAN; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REMISSION; SEIZURE; SPLENECTOMY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; DEFICIENCY; GENETICS; IMMUNOLOGY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADAM PROTEINS; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; APTAMERS, NUCLEOTIDE; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; PLATELET AGGREGATION INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECOMBINANT PROTEINS; REMISSION INDUCTION; SINGLE-DOMAIN ANTIBODIES; SPLENECTOMY; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84902284685     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1376883     Document Type: Article

References (51)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc: 1924; 24 21 24
2. Moake J. L., Rudy C. K., Troll J. H., et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med: 1982; 307 23 1432 1435
3. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med: 1998; 339 22 1578 1584
4. Tsai H. M., Lian E. C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med: 1998; 339 22 1585 1594
5. Moake J. L. Thrombotic microangiopathies. N Engl J Med: 2002; 347 8 589 600
6. Knöbl P. N. Treatment of thrombotic microangiopathy with a focus on new treatment options. Hamostaseologie: 2013; 33 2 149 159
7. Scully M., Hunt B. J., Benjamin S., et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol: 2012; 158 3 323 335
8. Fontana S., Kremer Hovinga J. A., Lämmle B., Mansouri Taleghani B. Treatment of thrombotic thrombocytopenic purpura. Vox Sang: 2006; 90 4 245 254
9. Riedl M., Orth-Höller D., Würzner R. An update on the thrombotic microangiopathies hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). 2014; 40 413 415
10. Lämmle B., Kremer Hovinga J. A., Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost: 2005; 3 8 1663 1675
11. Chapman K., Seldon M., Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost: 2012; 38 1 47 54
12. Tripodi A., Peyvandi F., Chantarangkul V., et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost: 2008; 6 9 1534 1541
13. Kokame K., Kokubo Y., Miyata T. Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw-Schulman syndrome. J Thromb Haemost: 2011; 9 8 1654 1656
14. Miyata T., Kokame K., Matsumoto M., Fujimura Y. ADAMTS13 activity and genetic mutations in Japan. Hamostaseologie: 2013; 33 2 131 137
15. Fujimura Y., Matsumoto M., Isonishi A., et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost: 2011; 9 01 283 301
16. Hassenpflug W. A., Budde U., Schneppenheim S., Schneppenheim R. Inherited thrombotic thrombocytopenic purpura in children. Semin Thromb Hemost: 2014; 40 4 487 492
17. Scheiflinger F., Knöbl P., Trattner B., et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood: 2003; 102 9 3241 3243
18. Tsai H. M. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost: 2012; 38 5 469 482
19. Schaller M., Studt J. D., Voorberg J., Kremer Hovinga J. A. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie: 2013; 33 2 121 130
20. Ferrari S., Knöbl P., Kolovratova V., et al. Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost: 2012; 10 1 156 158
21. Ferrari S., Palavra K., Gruber B., et al. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica: 2014; 99 4 779 787
22. Rock G. A., Shumak K. H., Buskard N. A., et al. Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med: 1991; 325 6 393 397
23. Cataland S. R., Scully M. A., Paskavitz J., et al. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol: 2011; 86 1 87 89
24. Falter T., Alber K. J., Scharrer I. Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes. Hamostaseologie: 2013; 33 2 113 120
25. Deford C. C., Reese J. A., Schwartz L. H., et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood: 2013; 122 12 2023 2029, quiz 2142
26. Som S., Deford C. C., Kaiser M. L., et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion: 2012; 52 12 2525 2532, quiz 2524
27. Bobbio-Pallavicini E., Porta C., Centurioni R., et al. The Italian Cooperative Group for TTP. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. Eur J Haematol: 1994; 52 4 222 226
28. Beloncle F., Buffet M., Coindre J. P., et al. Thrombotic Microangiopathies Reference Center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion: 2012; 52 11 2436 2444
29. Perosa F., Prete M., Racanelli V., Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med: 2010; 267 3 260 277
30. Knoebl P., Koder S., Schellongowski P., et al. Monitoring of ADAMTS13 in patients with thrombotic thrombocytopenic purpura: prediction of response to therapy, risk of relapse, and long- term outcome. Blood: 2008; 112 2291
31. Froissart A., Buffet M., Veyradier A., et al. French Thrombotic Microangiopathies Reference Center; Experience of the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Crit Care Med: 2012; 40 1 104 111
32. Scully M., McDonald V., Cavenagh J., et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood: 2011; 118 7 1746 1753
33. Bobbio-Pallavicini E., Gugliotta L., Centurioni R., et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica: 1997; 82 4 429 435
34. Rosove M. H., Ho W. G., Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med: 1982; 96 1 27 33
35. Bobbio-Pallavicini E., Porta C., Tacconi F., et al. Italian Cooperative Group for Thrombotic Thrombocytopenic Purpura. Intravenous prostacyclin (as epoprostenol) infusion in thrombotic thrombocytopenic purpura. Four case reports and review of the literature. Haematologica: 1994; 79 5 429 437
36. Waldner H. The role of innate immune responses in autoimmune disease development. Autoimmun Rev: 2009; 8 5 400 404
37. Kappers-Klunne M. C., Wijermans P., Fijnheer R., et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol: 2005; 130 5 768 776
38. Swisher K. K., Terrell D. R., Vesely S. K., Kremer Hovinga J. A., Lämmle B., George J. N. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion: 2009; 49 5 873 887
39. Coppo P., Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med: 2012; 41 3 Pt 2 e163 e176
40. Schiviz A., Wuersch K., Piskernik C., et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood: 2012; 119 25 6128 6135
41. Plaimauer B., Kremer Hovinga J. A., Juno C., et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost: 2011; 9 5 936 944
42. Bartunek J., Barbato E., Heyndrickx G., Vanderheyden M., Wijns W., Holz J. B. Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor. J Cardiovasc Transl Res: 2013; 6 3 355 363
43. Mayr F. B., Knöbl P., Jilma B., et al. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion: 2010; 50 5 1079 1087
44. Knöbl P., Jilma B., Gilbert J. C., Hutabarat R. M., Wagner P. G., Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion: 2009; 49 10 2181 2185
45. Jilma B., Paulinska P., Jilma-Stohlawetz P., Gilbert J. C., Hutabarat R., Knöbl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost: 2010; 104 3 563 570
46. Jilma-Stohlawetz P., Knöbl P., Gilbert J. C., Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost: 2012; 108 2 284 290
47. Cataland S. R., Peyvandi F., Mannucci P. M., et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol: 2012; 87 4 430 432
48. Siller-Matula J. M., Merhi Y., Tanguay J. F., et al. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol: 2012; 32 4 902 909
49. Kelly G. S. Clinical applications of N-acetylcysteine. Altern Med Rev: 1998; 3 2 114 127
50. Chen J., Reheman A., Gushiken F. C., et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest: 2011; 121 2 593 603
51. Li G. W., Rambally S., Kamboj J., et al. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion: 2013;; doi: 10.1111/trf.12440